Phase 2 N=31 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
Psoriasis-Type Psoriasis · Plaque-Type Psoriasis
Primary: Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase — 25; 13; 3; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Transdermal Electroacupuncture for Opioid Detoxification
Opioid Dependency
Primary: Percent of Participants Using Drugs — 35; 77 percent
Phase 2 N=99 Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate
HIV-1 Infection
Primary: Absolute Change in Relative FMD (%) — 0.60; 0.50 % FMD — p=0.28
Phase 3 N=293 GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
Renal Failure · Hemodialysis
Primary: Target Lesion Primary Patency at 6 Months — 52.9; 35.5 Percentage of Subjects
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
Phase 2 N=20 Kudzu Treatment for Alcohol Abuse
Alcohol Consumption
Primary: Drinking Behaviors — 3.4; 1.9 beers consumed
Phase 3 N=106 Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Primary: Part A: Number of Participants With Adverse Events (AEs) — 8; 4; 1; 3 participants
Phase 3 N=849 Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005
Phase 2 N=45 Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) · Adult Acute Myeloblastic Leukemia
Primary: Compete Remission (CR) Rate — 28 percentage of subjects
Phase 2 N=10 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
Age-Related Macular Degeneration · Choroidal Neovascularization
Primary: To Assess the Safety & Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD — 0…
Phase 3 N=361 A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks — -1.44; -0.90 percentage of HbA1c — p=<0.001
Phase 2 N=158 Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline — 45; 71 days to flare — p=0.2738
Phase 1 N=34 Preventing Depression in the Children of Depressed African American Mothers
Depression
Primary: Children Depression Inventory (CDI) — 47.64; 47.00; 42.11; 43.83 T scores — p=.015
Phase 2 N=253 Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Heart Failure · Elevated Serum Uric Acid
Primary: A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged. — 58; 58; 54; 43 participants
Phase 2 N=28 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Tuberous Sclerosis · Subependymal Giant Cell Astrocytoma
Primary: Number With Observed Adverse Side Effects — 26; 25; 15; 14 participants